EUVIMEDEUVIMED entdecken
Open Access

Bypassing Blood‐Brain Barrier and Glucose Dependency of Anti‐Glioblastoma Drug Candidates Targeting Mitochondrial Respiration

Charles H Ingraham, Diana Polania Villanueva, Annamarie Macaluso, Annelise Tramuta, Cecilia Vittori, Jean-Jacques Hunter, Monika Rak, Pier Paolo Claudio, Mohamed A Ibrahim, Luis Del Valle, Francesca Peruzzi, Branko S Jursic und 1 weitere

Journal of Cellular Physiology · 2025

DOI: 10.1002/jcp.70062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Physiology, 2025. Verfasst von Charles H Ingraham und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interdisciplinary Oncology, LSU Health Sciences Center, New Orleans, Louisiana, USA. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Mitochondria, Glioblastoma, Glucose. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We attempt to address two key therapeutic obstacles affecting glioblastoma patients: low ability of anticancer drugs to penetrate the blood‐brain barrier (BBB), and temozolomide (TMZ) resistance, by targeting mitochondrial respiration of glioblastoma cells. We designed and tested over 100 new compounds based on the chemical structure of fenofibrate (FF), which in its prodrug form is cytotoxic to cancer cells by causing severe impairment of mitochondrial respiration. The compounds were designed using two key predictive tools: central nervous system–multiparameter optimization (CNS‐MPO) and BBB_SCORE. These algorithms assess how effectively compounds can penetrate the BBB. We initially selected PP1 as a lead compound by testing its BBB penetration, metabolic performance, and antitumoral efficacy. PP1 accumulated in brain tumors and triggered glioblastoma cell death. However, PP1‐induced inhibition of mitochondrial respiration was followed by an immediate glycolytic response, which attenuated PP1 toxicity in a glucose‐dependent manner. To bypass this limitation, we tested two strategies: (1) the use of PP1 in combination with glycolysis inhibitors; and (2) introduction of a new compound, PP211, which inhibited mitochondrial respiration in the absence of a concomitant increase of glycolysis. Although the combination of PP1 with glycolysis inhibitors was very effective in vitro, this drug combination demonstrated elevated toxicity in mice. PP211, instead, attenuated TMZ‐resistant tumor growth and prolonged mouse survival with only minimal general animal toxicity. In summary, we developed and tested a novel mitochondria‐targeting drug candidate, PP211, which effectively crosses the BBB, overcomes TMZ resistance, and induces tumor cell death independently of glucose levels—while exhibiting minimal systemic toxicity in preclinical models. These findings support further development of PP211 for glioblastoma therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood-Brain BarrierMitochondriaGlioblastomaGlucoseBrain NeoplasmsAntineoplastic AgentsAnimalsHumansCell Line, TumorGlycolysisTemozolomideMiceXenograft Model Antitumor AssaysCell RespirationDrug Resistance, Neoplasm

Stichwörter der Autor:innen

blood‐brain barrierdrug developmentglioblastomamitochondrial respiration

Substanzen

GlucoseTemozolomideAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Interdisciplinary Oncology, LSU Health Sciences Center, New Orleans, Louisiana, USA.
  • Department of Neuroscience, Tulane University, New Orleans, Louisiana, USA.
  • Department of Cell Biology, Faculty of Biochemistry, Biphysics and Biotechnology, Jagiellonian University, Cracow, Poland.
  • Department of Pharmacology & Toxicology, Cancer Center & Research Institute, School of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
  • National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, Oxford, Mississippi, USA.
  • Department of Chemistry, University of New Orleans, New Orleans, Louisiana, USA.

ORCID-Profile: Krzysztof Reiss

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Ingraham, C. H., Villanueva, D. P., Macaluso, A., Tramuta, A., Vittori, C., Hunter, J. J., Rak, M., Claudio, P. P., Ibrahim, M. A., Del Valle, L., Peruzzi, F., Jursic, B. S., & Reiss, K. (2025). Bypassing Blood‐Brain Barrier and Glucose Dependency of Anti‐Glioblastoma Drug Candidates Targeting Mitochondrial Respiration. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.70062

Vancouver

Ingraham CH, Villanueva DP, Macaluso A, Tramuta A, Vittori C, Hunter JJ, et al. Bypassing Blood‐Brain Barrier and Glucose Dependency of Anti‐Glioblastoma Drug Candidates Targeting Mitochondrial Respiration. Journal of Cellular Physiology. 2025. doi:10.1002/jcp.70062

BibTeX
@article{Ingraham2025,
  author = {Ingraham, Charles H and Villanueva, Diana Polania and Macaluso, Annamarie and Tramuta, Annelise and Vittori, Cecilia and Hunter, Jean-Jacques and Rak, Monika and Claudio, Pier Paolo and Ibrahim, Mohamed A and Del Valle, Luis and Peruzzi, Francesca and Jursic, Branko S and Reiss, Krzysztof},
  title = {Bypassing Blood‐Brain Barrier and Glucose Dependency of Anti‐Glioblastoma Drug Candidates Targeting Mitochondrial Respiration},
  journal = {Journal of Cellular Physiology},
  year = {2025},
  doi = {10.1002/jcp.70062}
}
Kostenlos starten →